TECHNEGAS KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNEGAS KIT (TECHNEGAS KIT).
Technetium Tc-99m generator that produces pertechnetate ion, which is taken up by thyroid, salivary glands, stomach, and choroid plexus; also used for radiolabeling of other compounds.
| Metabolism | Not metabolized; excreted primarily by the kidneys via glomerular filtration. |
| Excretion | Renal: 100% as unchanged pertechnetate (99mTcO4-); biliary/fecal: negligible |
| Half-life | Physical half-life of 99mTc: 6.02 hours; effective half-life after inhalation: approximately 6.02 hours (clearance limited by physical decay, as the agent is inert) |
| Protein binding | Minimal; <5% bound to plasma proteins |
| Volume of Distribution | Not applicable as Vd; distributed within alveolar space and then cleared via decay and exhalation; no systemic distribution |
| Bioavailability | Inhalation: 100% of delivered dose reaches alveoli; route-specific |
| Onset of Action | Inhalation: immediate (within seconds) for lung ventilation imaging |
| Duration of Action | Inhalation: imaging window up to 30 minutes post-administration; clinical utility limited by physical half-life (6.02 hours) and rapid clearance from lungs |
Inhalation: 740-1110 MBq (20-30 mCi) of Technetium-99m DTPA aerosol, administered via nebulizer over 3-5 minutes.
| Dosage form | AEROSOL |
| Renal impairment | No dose adjustment required for Technetium-99m DTPA as it undergoes minimal renal clearance; however, excretion may be delayed in severe renal impairment (GFR <30 mL/min) but no dose reduction is recommended. |
| Liver impairment | No dose adjustment required; Technetium-99m DTPA is not hepatically metabolized and is primarily cleared via glomerular filtration. |
| Pediatric use | Weight-based dosing: 3.7-11.1 MBq/kg (0.1-0.3 mCi/kg) via nebulizer inhalation, not to exceed adult dose. Administer over 3-5 minutes. |
| Geriatric use | No specific dose adjustment; use standard adult dose. Monitor for adequate inhalation technique due to potential age-related pulmonary changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNEGAS KIT (TECHNEGAS KIT).
| Breastfeeding | Technetium-99m is excreted into breast milk. The American College of Radiology recommends interrupting breastfeeding for at least 4 hours after administration, or longer depending on the specific radiopharmaceutical and administered activity. M/P ratio not available for technetium-99m. |
| Teratogenic Risk | Technetium Tc-99m generator eluate is not known to be teratogenic. However, exposure to ionizing radiation from technetium-99m poses a potential risk to the fetus, especially during the first trimester where organogenesis occurs. The risk is dose-dependent and should be weighed against the benefit of the diagnostic procedure. Use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to technetium or any component of the kit"]
| Precautions | ["Risk of allergic reactions including anaphylaxis","Use caution in patients with renal impairment due to altered elimination","Pregnancy category C; avoid in pregnancy unless benefit outweighs risk","Lactation: discontinue breastfeeding or avoid use"] |
Loading safety data…
| Fetal Monitoring | Monitoring of radioactivity exposure to the fetus is not typically performed clinically. Appropriate radiation safety practices should be followed to minimize fetal dose. No specific maternal or fetal monitoring is required. |
| Fertility Effects | No known effects on fertility from technetium-99m at diagnostic doses. However, radiation exposure may affect gonadal tissue with high cumulative doses. Standard radiation safety precautions apply. |